Patents by Inventor Evan Snyder

Evan Snyder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190218511
    Abstract: The invention provides methods, compositions and kits for the identification and enrichment of progenitor cell lines obtained from pluripotent stem cells.
    Type: Application
    Filed: January 22, 2019
    Publication date: July 18, 2019
    Inventors: Dana Larocca, Paola Bignone, Michael D. West, Evan Snyder
  • Patent number: 10227561
    Abstract: The invention provides methods, compositions and kits for the identification and enrichment of progenitor cell lines obtained from pluripotent stem cells.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: March 12, 2019
    Assignees: Mandala Biosciences, LLC, BioTime, Inc., Sanford-Burnham Medical Research Institute
    Inventors: Dana Larocca, Paola Bignone, Michael D. West, Evan Snyder
  • Publication number: 20170121676
    Abstract: The invention provides methods, compositions and kits for the identification and enrichment of progenitor cell lines obtained from pluripotent stem cells.
    Type: Application
    Filed: November 2, 2015
    Publication date: May 4, 2017
    Inventors: David Larocca, Paola Bignone, Michael West, Evan Snyder
  • Patent number: 9175263
    Abstract: The invention provides methods, compositions and kits for the identification and enrichment of progenitor cell lines obtained from pluripotent stem cells.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: November 3, 2015
    Inventors: David Larocca, Paola Bignone, Michael West, Evan Snyder
  • Publication number: 20140099712
    Abstract: The invention provides methods, compositions and kits for the identification and enrichment of progenitor cell lines obtained from pluripotent stem cells.
    Type: Application
    Filed: August 21, 2013
    Publication date: April 10, 2014
    Applicant: MANDALA BIOSCIENCES, LLC
    Inventors: David Larocca, Paola Bignone, Michael West, Evan Snyder
  • Publication number: 20110002897
    Abstract: Disclosed are compositions and methods for producing neural cells from stem cells and uses thereof.
    Type: Application
    Filed: June 10, 2010
    Publication date: January 6, 2011
    Applicant: Burnham Institute for Medical Research
    Inventors: Evan Snyder, Ilyas Singec
  • Patent number: 7375343
    Abstract: A neutron detecting and method of use for a semiconducting material having a formula of M1M2B14 where M1 is aluminum, magnesium, silver, sodium or scandium and M2 is boron, chromium, erbium, holmium, lithium, magnesium, thulium, titanium, yttrium, or gadolinium.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: May 20, 2008
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Bruce A. Cook, John Evan Snyder, Alan P. Constant, Yun Tian
  • Publication number: 20070031391
    Abstract: The present invention is based upon a surprising finding that stem cells, more particularly neural stem cells, can migrate throughout a brain tumor and track metastatic brain tumor cells. The invention provides a method for treating brain tumors by administering genetically engineered neural stem cells in an individual affected by brain tumors. The invention also provides a method of preparing genetically engineered neural stem cells and a composition comprising genetically engineered neural stem cells in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: October 12, 2006
    Publication date: February 8, 2007
    Applicants: Children's Medical Center Corporation, The General Hospital Corporation, Northeastern Ohio Universities College of Medicine
    Inventors: Evan Snyder, Xandra Breakefield, Karen Aboody, Ulrich Herrlinger, William Lynch
  • Publication number: 20070010011
    Abstract: Stem cells, including mammalian, and particularly primate primordial stem cells (pPSCs) such as human embryonic stem cells (hESCs), hold great promise for restoring cell, tissue, and organ function. However, cultivation of stem cells, particularly undifferentiated hESCs, in serum-free, feeder-free, and conditioned-medium-free conditions remains crucial for large-scale, uniform production of pluripotent cells for cell-based therapies, as well as for controlling conditions for efficiently directing their lineage-specific differentiation. This instant invention is based on the discovery of the formulation of minimal essential components necessary for maintaining the long-term growth of pPSCs, particularly undifferentiated hESCs. Basic fibroblast growth factor (bFGF), insulin, ascorbic acid, and laminin were identified to be both sufficient and necessary for maintaining hESCs in a healthy self-renewing undifferentiated state capable of both prolonged propagation and then directed differentiation.
    Type: Application
    Filed: May 17, 2006
    Publication date: January 11, 2007
    Applicant: The Burnham Institute
    Inventors: Xuejun Parsons, Evan Snyder
  • Publication number: 20050233446
    Abstract: Stem cells, including mammalian, and particularly primate primordial stem cells (pPSCs) such as human embryonic stem cells (hESCs), hold great promise for restoring cell, tissue, and organ function. However, cultivation of stem cells, particularly undifferentiated hESCs, in serum-free, feeder-free, and conditioned-medium-free conditions remains crucial for large-scale, uniform production of pluripotent cells for cell-based therapies, as well as for controlling conditions for efficiently directing their lineage-specific differentiation. This instant invention is based on the discovery of the formulation of minimal essential components necessary for maintaining the long-term growth of pPSCs, particularly undifferentiated hESCs. Basic fibroblast growth factor (bFGF), insulin, ascorbic acid, and laminin were identified to be both sufficient and necessary for maintaining hESCs in a healthy self-renewing undifferentiated state capable of both prolonged propagation and then directed differentiation.
    Type: Application
    Filed: December 31, 2004
    Publication date: October 20, 2005
    Inventors: Xuejun Parsons, Evan Snyder
  • Publication number: 20050169897
    Abstract: One of the impediments to the treatment of some human brain tumors (e.g. gliomas) has been the degree to which they expand, migrate widely, and infiltrate normal tissue. We demonstrate that a clone of multipotent neural progenitor stem cells, when implanted into an experimental glioma, will migrate along with and distribute themselves throughout the tumor in juxtaposition to widely expanding and aggressively advancing tumor cells, while continuing to express a foreign reporter gene. Furthermore, drawn somewhat by the degenerative environment created just beyond the infiltrating tumor edge, the neural progenitor cells migrate slightly beyond and surround the invading tumor border. When implanted at a distant sight from the tumor bed (e.g., into normal tissue, into the contralateral hemisphere, into the lateral ventricles) the donor neural progenitor/stem cells will migrate through normal tissue and specifically target the tumor cells.
    Type: Application
    Filed: September 22, 2004
    Publication date: August 4, 2005
    Applicants: Children's Medical Center Corporation, The General Hospital Corporation, Northeastern Ohio Universities of Medicine
    Inventors: Evan Snyder, Karen Aboody, Xandra Breakefield, William Lynch
  • Publication number: 20050069526
    Abstract: Methods, kits and compositions for improving a subject's recovery from CNS injury are disclosed. In certain aspects, a method may include administering to a subject cells and a neural stimulant. Recovery may be manifest by improvements in sensorimotor or cognitive abilities, e.g., improved limb movement and control or improved speech capability. In certain embodiments, subject methods can be used as part of a treatment for damage resulting from ischemia, hypoxia or trauma.
    Type: Application
    Filed: September 30, 2003
    Publication date: March 31, 2005
    Inventors: Seth Finklestein, Evan Snyder
  • Publication number: 20050019313
    Abstract: The present invention relates to the field of cellular and molecular therapy with modified (genetically or growth factor engineered) and unmodified stem cells (SCs). More particularly, the invention relates to a method of systemic treatment of central nervous system (CNS) and other tumors in both intracranial/intraspinal and extracranial/extraspinal sites, using neural stem cells (NSCs), a prototype for solid organ, non-hematopoietic stem cells.
    Type: Application
    Filed: March 15, 2001
    Publication date: January 27, 2005
    Inventors: Evan Snyder, Karen Aboody, Alice Brown, Xandra Breakefield